By Fineline Cube 
Mirxes Holding Company Limited (HKG: 2629) announced that its clinical diagnostic laboratory, M Diagnostics Philippines Inc., has officially signed a Strategic Memorandum of Understanding (MOU) with local Philippine wellness enterprise GAIA Health and Wellness Company, a partnership aimed at advancing evidence‑based early cancer screening and precision diagnostics across the Philippine market.
Partnership Overview
| Item | Detail |
|---|---|
| Company | Mirxes (HKG: 2629) |
| Local Partner | GAIA Health and Wellness Company (Philippines) |
| Executing Entity | M Diagnostics Philippines Inc. |
| Agreement Type | Strategic Memorandum of Understanding (MOU) |
| Focus | Early cancer screening, precision diagnostics, health education |
| Announcement Date | 25 Aug 2026 |
Three Core Areas of Cooperation
- Public Health Education & Awareness: Raising public awareness of evidence‑based early cancer screening, enabling easier access to clinically validated diagnostic services, and empowering individuals to understand their health status and proactively plan long‑term health management.
- High‑Precision Diagnostic Services: Leveraging Mirxes’ dual CAP‑ and ISO‑accredited diagnostic laboratory in Singapore to provide highly accurate testing and reporting services tailored to the Philippine market.
- Market Reach via Local Network: Utilizing GAIA Health’s local health service network to accelerate the adoption of advanced diagnostic technologies and clinical genomics services across a broader population.
Joint Initiatives & Innovation Pipeline
- Joint Health Initiatives: Both parties intend to launch joint initiatives to actively promote evidence‑based early screening concepts across the Philippines.
- Aging & Longevity Testing: The collaboration extends to the local validation of innovative testing projects related to aging and longevity, aligning with rising regional demand for preventive and longevity‑oriented health services.
Strategic Outlook
- Southeast Asia Expansion: The MOU reinforces Mirxes’ strategy of commercializing its liquid biopsy and diagnostic platforms through local partnerships across Southeast Asian markets.
- Accreditation as Moat: Mirxes’ CAP‑ and ISO‑accredited Singapore laboratory provides a quality credential that supports cross‑border diagnostic service delivery and clinician trust.
- Preventive Health Tailwind: Growing awareness of early cancer detection in the Philippines — where late‑stage diagnosis remains common — creates a favorable environment for partnerships combining international technology with local distribution networks.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the cooperation between Mirxes and GAIA Health, including planned health initiatives, diagnostic service rollout and validation of testing projects. Actual results may differ due to risks including execution timelines, regulatory requirements and market adoption.-Fineline Info & Tech